Drug Trial Radar · NCT04717414
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
313
Actual
Start
Feb 25, 2021
Primary completion
May 26, 2025
Study completion Aug 18, 2032
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period. Following the Day 169 Response Assessment, subjects who did not show clinical benefit will have the option to unblind. Subjects who were on placebo during the Blinded Core Treatment Period will have the opportunity to crossover into the Open-Label Extension Treatment Period and receive Luspatercept.
Conditions
- Myeloproliferative Disorders
- Myelofibrosis
- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Anemia
Interventions
ACE-536Drug
Subcutaneous Injection
PlaceboOther
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12)Time frame: From randomization to week 36 (Approximately 36 Weeks)
Locations
185 sites in 26 countries. Site status is shown where the registry gives one.
Local Institution - 110
Los Angeles, California
Local Institution - 135
Orlando, Florida
Local Institution - 133
Plantation, Florida
Local Institution - 112
Chicago, Illinois
Local Institution - 124
Lexington, Kentucky
Local Institution - 114
Ann Arbor, Michigan
Local Institution - 108
St Louis, Missouri
John Theurer Cancer Center
Hackensack, New Jersey
Mount Sinai Medical Center
New York, New York
University of Pittsburg Medical Center
Pittsburgh, Pennsylvania
Allegheny Health Network
Pittsburgh, Pennsylvania
Local Institution - 130
Knoxville, Tennessee
The University of Texas - MD Anderson Cancer Center
Houston, Texas
Local Institution - 119
Salt Lake City, Utah
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Local Institution - 172
Ciudad Autónoma de BuenosAires, Buenos Aires, Argentina
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
Gosford Hospital
Gosford, Australia
Royal Hobart Hospital
Hobart, Australia
Monash Medical Centre
Clayton, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Local Institution - 272
Graz, Austria
Krankenhaus der Elisabethinen Linz, I Interne Abteilung
Linz, Austria
Local Institution - 271
Vienna, Austria
Local Institution - 274
Vienna, Austria
Local Institution - 318
Bruges, Belgium
Local Institution - 312
Brussels, Belgium
Local Institution - 313
Hasselt, Belgium
Uz Leuven
Leuven, Belgium
Local Institution - 319
Liège, Belgium
Local Institution - 316
Roeselare, Belgium
Local Institution - 315
Verviers, Belgium
Cliniques Universitaires UCL de Mont-Godine
Yvoir, Belgium
Local Institution - 181
Calgary, Alberta, Canada
Local Institution - 179
Edmonton, Alberta, Canada
Local Institution - 183
Vancouver, British Columbia, Canada
University Hospital - London Health Sciences Centre
London, Ontario, Canada
Local Institution - 180
Toronto, Ontario, Canada
Local Institution - 177
Montreal, Quebec, Canada
Showing 40 of 185 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.